Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SABA vs ACTU: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SABA Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 4–4 Matrix Metrics)

SABA Overall Winner 6-Pillar Tally: SABA 2 – 2 ACTU (2 Tie) Matrix Metrics: SABA 4 – 4 ACTU

As of Nov 20, 2026, Saba Capital Income & Opportunities Fund II (SABA) is the stronger overall head-to-head candidate over Actuate Therapeutics, Inc. (ACTU) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). SABA carries a Unified Composite Score of 44.2/100 (HOLD) at $7.33 (N/M Forward P/E, N/A operating margin), whereas ACTU carries 35.1/100 (SELL) at $0.23 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: SABA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.9); meanwhile ACTU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SABA vs ACTU
SABA NYSE Head-to-Head Winner
Saba Capital Income & Opportunities Fund II
Institutional Equity
$7.33
-0.27% 1D
Market Cap $251.8M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.37β · 13% Vol
Unified Composite Score
44.2 / 100 HOLD
Tech 38.0 Fund 55.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.2%), weak momentum, RSI 30
RSI-14: 29.9 · SMA20: $7.56 · SMA50: $7.75
ACTU NASDAQ
Actuate Therapeutics, Inc. Common stock
Pharmaceutical Preparations
$0.23
+5.38% 1D
Market Cap $12.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.64β · 114% Vol
Unified Composite Score
35.1 / 100 SELL
Tech 25.0 Fund 37.0 Flow 50.0 Mom 49.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -41.7%), weak momentum, RSI 29
RSI-14: 28.8 · SMA20: $0.32 · SMA50: $0.56

6-Pillar Scorecard Institutional Category Breakdown (SABA 2 – 2 ACTU)

Columns: Metric · SABA · ACTU
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ACTU
Revenue Growth (YoY) N/A +0.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $251.8M $12.9M
3. Profitability & Quality ACTU
Gross Margin N/A N/A
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -553.8%
4. Balance Sheet & Cash Flow SABA
Cash Generation (TTM) N/A -$20M
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $0.34 Book/Sh · -553.8% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SABA
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SABA (4) vs ACTU (4)
Institutional Metric SABA ACTU Criterion Row Edge
Market Capitalization
Scale
$251.8M $12.9M Larger Scale SABA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +0.0% Higher Growth ACTU
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin ACTU
Net Profit Margin
Profitability
N/A 0.0% Higher Margin ACTU
Return on Equity (ROE)
Capital Efficiency
N/A -553.8% Higher ROE ACTU
52-Week Range Position
Momentum
4% ($7–$9) 1% ($0–$8) Stronger Trend SABA
Beta / 30D Volatility
Risk Regime
0.37β · 13% Vol 1.64β · 114% Vol Lower Realized Risk SABA
Unified Institutional Score
Composite Signal
44.2 / 100 (HOLD) 35.1 / 100 (SELL) Higher Composite SABA
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$20M ($0.34 Book/Sh · -553.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SABA +52.67 pp
SABA: -3.68% · ACTU: -56.35%
3M Horizon SABA +71.18 pp
SABA: -10.5% · ACTU: -81.68%
6M Horizon SABA +77.69 pp
SABA: -12.84% · ACTU: -90.53%
1Y Horizon SABA +80.11 pp
SABA: -16.04% · ACTU: -96.15%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SABA vs ACTU. Trailing 12-month operating profitability (SABA N/A vs ACTU 0.0%) and valuation multiples (SABA N/M vs ACTU N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SABA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
ACTU ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-553.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SABA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SABA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ACTU BREAKDOWN
136d in phase · OBV DISTRIBUTION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact ACTU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SABA Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with $251.8M market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ACTU Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $12.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SABA vs ACTU Key Questions & Quantitative Answers

As of Nov 20, 2026, Saba Capital Income & Opportunities Fund II (SABA) is the stronger overall head-to-head candidate over Actuate Therapeutics, Inc. (ACTU) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). SABA carries a Unified Composite Score of 44.2/100 (HOLD) at $7.33 (N/M Forward P/E, N/A operating margin), whereas ACTU carries 35.1/100 (SELL) at $0.23 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: SABA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.9); meanwhile ACTU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ACTU leads the Growth & Scale pillar: SABA posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ACTU at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, SABA generates N/A in USD-normalized revenue versus N/A for ACTU. In operating R&D and SG&A reinvestment, SABA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ACTU.

SABA and ACTU trade at balanced relative valuation multiples. SABA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ACTU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SABA (N/A ROE) versus ACTU (-553.8% ROE) capital efficiency.

In options market volatility and institutional positioning, SABA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.37β · 13% Vol realized risk). By comparison, ACTU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.64β · 114% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.